Valsartan-d9
Based on 1 Customer Validation
Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
For research use only. We do not sell to patients.
- Purity : 99.33%
- CAS No.: 1089736-73-1
- Formula: C24H20D9N5O3
- Molecular Weight:444.57
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-B0205S
Candesartan-d4Stable Isotope -
HY-18204
ValsartanAngiotensin II Receptor Antagonist -
HY-17512A
Losartan potassiumAT1 Antagonist -
HY-15834A
Eprosartan mesylateAngiotensin II Receptor Antagonist -
HY-17512AR
Losartan potassium (Standard)AT1 Antagonist -
HY-17512
LosartanAngiotensin II Receptor Antagonist -
HY-12765S
Losartan-d4 (carboxylic acid)Stable Isotope -
HY-B0195
TranilastAnti-allergic Agent -
HY-18204R
Valsartan (Standard)Angiotensin II Receptor Antagonist -
HY-14914S
Azilsartan-d5Angiotensin II Receptor Antagonist -
HY-15778A
AVE 0991 sodium saltAng-(1-7) Receptor Agonist -
HY-B0205
CandesartanAngiotensin II AT1-Receptor Blocker
All Angiotensin Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
|
AT1 Receptor |
In Vitro
Valsartan is a synthetic non-peptide angiotensin II type 1 receptor antagonist that dilates blood vessels and reduces blood pressure by blocking the action of angiotensin. Valsartan significantly decreases the expression of AT1R in ageing aorta endothelial cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1089736-73-1
-
Unlabeled CAS 137862-53-4
-
Appearance Solid
-
Molecular Weight 444.57
-
Formula C24H20D9N5O3
-
Color White to yellow
-
SMILES
CC(C)[C@@H](C(O)=O)N(C(C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)CC(C=C1)=CC=C1C2=CC=CC=C2C3=NN=NN3
-
Synonyms
CGP 48933-d9
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
Ethanol : ≥ 30 mg/mL (67.48 mM)
DMF : ≥ 30 mg/mL (67.48 mM)
DMSO : ≥ 30 mg/mL (67.48 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMF / DMSO | 1 mM | 2.2494 mL | 11.2468 mL | 22.4936 mL | 56.2341 mL |
| 5 mM | 0.4499 mL | 2.2494 mL | 4.4987 mL | 11.2468 mL | |
| 10 mM | 0.2249 mL | 1.1247 mL | 2.2494 mL | 5.6234 mL | |
| 15 mM | 0.1500 mL | 0.7498 mL | 1.4996 mL | 3.7489 mL | |
| 20 mM | 0.1125 mL | 0.5623 mL | 1.1247 mL | 2.8117 mL | |
| 25 mM | 0.0900 mL | 0.4499 mL | 0.8997 mL | 2.2494 mL | |
| 30 mM | 0.0750 mL | 0.3749 mL | 0.7498 mL | 1.8745 mL | |
| 40 mM | 0.0562 mL | 0.2812 mL | 0.5623 mL | 1.4059 mL | |
| 50 mM | 0.0450 mL | 0.2249 mL | 0.4499 mL | 1.1247 mL | |
| 60 mM | 0.0375 mL | 0.1874 mL | 0.3749 mL | 0.9372 mL |
Valsartan-d9 Related Classifications
HY-18204S Related Classifications
Powered by Bioz